Filing Analysis
Cumberland Pharmaceuticals Inc. announced a delay in the release of long-term safety and efficacy data from its Phase 2 FIGHT DMD trial for ifetroban. The company previously indicated this data would be presented in August 2026, but now states the data is not yet available.
🚩 Red Flags
- Delay in clinical trial data presentation can be perceived as a setback in the development timeline for a key pipeline asset.
📋 Key Facts
- The data pertains to the Phase 2 FIGHT DMD trial evaluating ifetroban for Duchenne muscular dystrophy (DMD) heart disease.
- The data involves the ongoing open-label extension of the trial.
- The company will no longer present the data in August 2026 as previously anticipated.
- The company intends to present the information at a future date once it becomes available.
Cumberland Pharmaceuticals Inc. filed an 8-K to announce the release of its financial results and company update for the three and six months ended June 30, 2026.
📋 Key Facts
- Report date: August 4, 2026
- Reporting period: Three and six months ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) containing financial results and a company update.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
Cumberland Pharmaceuticals has declared a special cash dividend of $1.50 per share following a strategic transaction with Apotex Health Corp that resulted in higher-than-expected net cash.
🚩 Red Flags
- None identified; the filing describes significant cash inflows and capital return programs.
📋 Key Facts
- Board authorized a special cash dividend of $1.50 per share of common stock.
- Record date for the dividend is July 23, 2026; payment expected on or about July 31, 2026.
- The company received $100 million in cash from a strategic transaction with Apotex Health Corp for its FDA-approved product line.
- An additional $11 million is expected from inventory and transitional support services.
- Authorized an open-market share repurchase program of up to $5 million.
Cumberland Pharmaceuticals has completed the sale of its core FDA-approved product portfolio to Nuvo Pharmaceuticals (an affiliate of Apotex Inc.) for $100 million. The company will pivot to focus on its remaining 'Retained Programs' involving ifetroban product candidates.
🚩 Red Flags
- Significant loss of core revenue-generating assets (the FDA-approved product portfolio).
- Departure of key management personnel following the asset sale.
- Pivot to a high-risk R&D model focusing on 'Retained Programs' rather than established commercial products.
📋 Key Facts
- Completed sale of FDA-approved products (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100 million in aggregate cash consideration.
- The transaction was approved by shareholders on June 24, 2026.
- Company repaid approximately $5.3 million to terminate the Pinnacle Bank Revolving Credit Loan Agreement.
- Retained assets include ifetroban product candidates and Cumberland Emerging Technologies, Inc.
- Two key executives (VP Sales & Marketing and VP Trade & Distribution/Compliance) are resigning effective July 31, 2026, to join an Apotex affiliate.
Cumberland Pharmaceuticals Inc. shareholders have approved a strategic transaction to integrate the company's commercial products with the U.S. branded business of an Apotex affiliate. This involves the sale of substantially all of the company's FDA-approved commercial products and related assets.
🚩 Red Flags
- Sale of substantially all assets: This typically indicates a fundamental change in the company's business model or a liquidation-style event for the existing entity.
- Potential loss of core revenue streams as the FDA-approved commercial products are being integrated/sold to Apotex.
📋 Key Facts
- Special Meeting held on June 24, 2026, in Nashville, Tennessee.
- Shareholders approved the Asset Purchase Agreement dated April 22, 2026.
- The transaction involves Nuvo Pharmaceuticals (Ireland) DAC, Apotex Inc., and Cumberland Pharmaceuticals Inc.
- The sale is characterized as a sale of substantially all of the Company's property and assets under Tennessee law.
- Approval received with 70.03% of outstanding votes in favor and 99.84% of votes cast in favor.
- Quorum was met with 10,509,626 shares (approx. 70.14% of outstanding shares) represented.
Cumberland Pharmaceuticals Inc. announced its financial results and provided a company update for the first quarter ended March 31, 2026.
📋 Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The report was filed and the event occurred on May 5, 2026.
- The information is furnished under Item 2.02 regarding Results of Operations and Financial Condition.
- The filing includes a press release as Exhibit 99.1.
Cumberland Pharmaceuticals reported the results of its annual meeting of shareholders held on April 21, 2026. Shareholders elected two Class I directors, ratified the company's independent auditor, and approved executive compensation matters including a triennial vote frequency.
📋 Key Facts
- Kenneth J. Krogulski and Caroline R. Young were elected as Class I Directors with 99.52% and 98.66% of votes in favor, respectively.
- Carr, Riggs & Ingram, LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 99.82% approval.
- Shareholders approved the advisory vote on executive compensation with 99.82% support.
- Shareholders voted for a frequency of 'Every Three Years' for future advisory votes on executive compensation, receiving 7,844,848 votes compared to 1,733,309 for 'Every Year'.
Cumberland Pharmaceuticals has entered into a definitive agreement to sell its entire portfolio of six FDA-approved commercial products to Apotex for $100 million in cash. Following the transaction, the company will pivot to focus exclusively on its ifetroban development pipeline and its interest in Cumberland Emerging Technologies.
🚩 Red Flags
- Divestiture of all current revenue-generating assets, leaving the company with no immediate source of commercial income.
- Significant pivot to a development-stage business model which carries higher clinical and regulatory risk.
- Four-year non-compete restriction limits the company's ability to leverage its existing commercial expertise in its primary markets.
📋 Key Facts
- Apotex will acquire Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ for $100,000,000 in cash.
- Cumberland retains its ifetroban product candidates and its subsidiary, Cumberland Emerging Technologies, Inc.
- Directors and executive officers holding approximately 41% of the company's common stock have signed voting and support agreements in favor of the deal.
- A termination fee of $4,000,000 (4% of deal value) is payable by Cumberland if it accepts a superior proposal or fails to obtain shareholder approval.
- The agreement includes a 4-year non-competition covenant and an 18-month employee non-solicitation provision.
- A potential milestone payment exists if Apotex secures a Vibativ supply contract with the U.S. Department of Health and Human Services within two years.
Cumberland Pharmaceuticals Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, via a press release on March 3, 2026.
📋 Key Facts
- The filing reports financial results for the three months and fiscal year ended December 31, 2025.
- The information was disclosed under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the results and a company update was included as Exhibit 99.1.
- The report was signed by John Hamm, Chief Financial Officer.
Cumberland Pharmaceuticals Inc. announced that the FDA has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients.
📋 Key Facts
- FDA granted Fast Track Designation for a novel oral therapy.
- The therapy targets a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients.
- Announcement date: February 4, 2026.
Cumberland Pharmaceuticals Inc. has executed an amendment to its existing revolving credit facility with Pinnacle Bank, extending the maturity date and maintaining a total borrowing capacity of $25 million.
🚩 Red Flags
- Debt is secured by 'substantially all' of the Company's assets, leaving little unencumbered collateral for future financing.
- The company remains subject to financial covenants (Minimum Fixed Charge Coverage Ratio) which could trigger default if cash flows fluctuate.
📋 Key Facts
- Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolting Credit Loan Agreement signed November 18, 2025.
- The amendment extends the maturity date of the debt to October 1, 2027.
- Total aggregate principal funding remains unchanged at up to $25 million (includes a $15 million immediate availability and an option for an additional $10 million).
- Interest rate is set at Benchmark Term SOFR plus 2.75%.
- The loan is collateralized by substantially all of the Company’s assets.
- Requires maintenance of a Minimum Fixed Charge Coverage Ratio.
Cumberland Pharmaceuticals Inc. filed an 8-K to furnish a press release containing company updates and financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 4, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished rather than filed under Section 18 of the Exchange Act
Cumberland Pharmaceuticals Inc. has entered into a strategic arrangement with RedHill Biopharma Ltd. to jointly commercialize Talicia, an FDA-approved treatment for Helicobacter pylori infection.
📋 Key Facts
- Strategic partnership announced on October 20, 2025, with RedHill Biopharma Ltd. (Nasdaq: RDHL).
- The agreement focuses on the joint commercialization of Talicia, an FDA-approved oral capsule for Helicobacter pylori infection.
- Talicia is indicated for adults and serves as a leading risk factor for gastric cancer.
Cumberland Pharmaceuticals Inc. issued an 8-K to furnish a press release containing the company's financial results and operational update for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 5, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished under Item 2.02 and not filed for purposes of Section 18 liability
Cumberland Pharmaceuticals Inc. filed an 8-K to furnish a press release containing the company's financial results and operational update for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 6, 2025
- Reporting period: Three months ended March 31, 2025
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished rather than filed under Section 18 of the Exchange Act
Cumberland Pharmaceuticals Inc. reported the results of its annual meeting of shareholders held on April 22, 2025. The filing confirms the election of three Class III Directors and the ratification of Carr, Riggs & Ingram, LLC as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual meeting held on April 22, 2025, in Nashville, Tennessee.
- Election of three Class III Directors: Gordon R. Bernard (98.6% in favor), Joseph C. Galante (99.2% in favor), and A.J. Kazimi (99.6% in favor).
- Ratification of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for the year ending December 31, 2025 (99.7% in favor).
Cumberland Pharmaceuticals announced that its Phase 2 FIGHT DMD clinical trial results were selected for a late-breaking presentation at the MDA Clinical & Scientific Conference. The trial reported significant cardiac benefits in patients with Duchenne muscular dystrophy.
📋 Key Facts
- Phase 2 FIGHT DMD clinical trial results selected for late-breaking presentation at the Muscular Dystrophy Association (MDA) Conference.
- Trial demonstrated 'significant cardiac benefits' for patients with Duchenne muscular dystrophy (DMD).
- The MDA conference is scheduled to take place in Dallas.
Cumberland Pharmaceuticals Inc. issued an 8-K to furnish a press release containing the company's financial results and operational update for the three months and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 4, 2025
- Reporting period: Three months and full year ended December 31, 2024
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information was furnished rather than filed under Section 18 of the Exchange Act
Cumberland Pharmaceuticals announced that the NMPA (China's regulatory authority) has approved Vibativ® (telavancin) injection. This follows a prior agreement granting SciClone Pharmaceuticals exclusive rights to register, promote, and distribute the product in China.
📋 Key Facts
- NMPA approval received for Vibativ® (telavancin) injection in China on February 18, 2025.
- SciClone Pharmaceuticals (Holdings) Limited holds exclusive rights to register, promote, and distribute the product in China.
- The announcement was made via an 8-K filing under Item 8.01.
Cumberland Pharmaceuticals, Inc. has increased the maximum aggregate offering price of common stock issuable under its existing Sales Agreement with H.C. Wainwright & Co., LLC by up to $10,000,000.
🚩 Red Flags
- Potential dilution for existing shareholders due to the increase in common stock issuable.
📋 Key Facts
- Increased maximum aggregate offering price by up to $10,000,000.
- The increase is under the existing Sales Agreement dated March 20, 2024.
- The offering is being conducted via an ATM (At-the-Market) style Sales Agreement with H.C. Wainwright & Co., LLC.
- Amendment to a previously filed prospectus supplement under Form S-3 (File No. 333-276052).
Cumberland Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial evaluating ifetroban for Duchenne muscular dystrophy (DMD) heart disease. The study represents a potential breakthrough as the first successful Phase 2 study targeting cardiac complications in DMD patients.
📋 Key Facts
- Announced positive top-line results from Phase 2 FIGHT DMD trial on February 4, 2025.
- The therapy being evaluated is ifetroban, an oral therapy for Duchenne muscular dystrophy (DMD) heart disease.
- Targeted condition: Cardiac complications in DMD patients, which is the leading cause of death in this population.
- Claimed as the first successful Phase 2 study specifically targeting cardiac complications in DMD.
Cumberland Pharmaceuticals announced FDA approval of a supplemental New Drug Application (sNDA) for its Acetadote product. The approval introduces a simplified dosing regimen that combines the first two bags of the standard IV infusion into a single, slower infusion.
📋 Key Facts
- FDA approved sNDA for Acetadote (N-acetylcysteine for injection).
- The approval covers a new dosing regimen designed to simplify administration.
- Acetadote is indicated to prevent or lessen liver injury after acetaminophen ingestion.
- Announcement date: December 9, 2024.
Cumberland Pharmaceuticals announced that the FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its drug candidate, Ifetroban, for treating cardiomyopathy in Duchenne muscular dystrophy (DMD). The company is currently conducting the Phase II FIGHT DMD™ trial.
📋 Key Facts
- FDA granted Orphan Drug Designation for Ifetroban for cardiomyopathy associated with DMD.
- FDA granted Rare Pediatric Disease Designation for Ifetroban for cardiomyopathy associated with DMD.
- The company is currently conducting the Phase II FIGHT DMD™ trial (multicenter, double-blind, placebo-controlled).
- Phase II study results are expected to be announced later in 2024.
Cumberland Pharmaceuticals Inc. filed this 8-K to furnish a press release containing the company's financial results and operational update for the three and nine months ended September 30, 2024.
📋 Key Facts
- The filing incorporates by reference a press release dated November 7, 2024 (Exhibit 99.1).
- The reported results cover the three and nine months ended September 30, 2024.
- The information is furnished under Item 2.02 of Form 8-K.
Cumberland Pharmaceuticals announced the publication of new real-world outcomes research in 'Frontiers of Pain Research' regarding its product Caldolor. The study suggests safety and healthcare resource advantages for Caldolor over ketorolac in adult and pediatric populations.
📋 Key Facts
- Publication date of research: November 5, 2024
- Journal name: Frontiers of Pain Research
- Product focus: Caldolor (ibuprofen) injection vs. ketorolac
- Key findings: Reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations.
Cumberland Pharmaceuticals announced that CMS has excluded its product, Caldolor, from the list of pharmaceuticals eligible for separate Medicare reimbursement under the NOPAIN Act. This decision contradicts the company's previous guidance and expectations regarding revenue streams related to non-opioid pain management.
🚩 Red Flags
- Significant regulatory setback regarding a core product (Caldolor).
- Discrepancy between management's previous guidance/expectations and the actual CMS determination.
- Potential impact on future revenue streams from hospital outpatient departments and ambulatory surgical centers.
📋 Key Facts
- CMS issued a ruling on November 1, 2024, regarding the Calendar Year 2025 Medicare Outpatient Prospective Payment System (OPPS).
- Caldolor was excluded from the list of products eligible for separate payment under the NOPAIN Act.
- CMS's reasoning is that Caldolor's FDA-approved indications do not explicitly mention 'post-operative' or 'post-surgical' use.
- The company had previously expected eligibility based on its clinical studies and arguments submitted to CMS in July 2023 and July 2024.
- The NOPAIN Act reimbursement period applies to products furnished between January 1, 2025, and January 1, 2028.
Cumberland Pharmaceuticals Inc. filed an 8-K to furnish a press release containing the company's financial results and operational update for the three and six months ended June 30, 2024.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results cover the periods ending June 30, 2024 (three and six months).
- A press release dated August 6, 2024, was issued as Exhibit 99.1.
- The report was signed by John Hamm, Chief Financial Officer.
Cumberland Pharmaceuticals Inc. issued an 8-K to furnish a press release containing the company's financial results and operational update for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Three months ended March 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information provided via press release attached as Exhibit 99.1
Cumberland Pharmaceuticals Inc. reported the results of its annual meeting of shareholders held on April 23, 2024. Shareholders approved the election of two Class II Directors and ratified the appointment of Carr, Riggs & Ingram, LLC as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual meeting held on April 23, 2024, in Nashville, Tennessee.
- Martin S. Brown, Jr. elected to Class II Director with 96.0% of votes in favor.
- James R. Jones elected to Class II Director with 94.5% of votes in favor.
- Carr, Riggs & Ingram, LLC ratified as independent registered public accounting firm for the year ending Dec 31, 2024, with 99.9% approval.
Cumberland Pharmaceuticals Inc. has entered into a Sales Agreement with H.C. Wainwright & Co., LLC to launch an 'at-the-market' (ATM) offering program. The company intends to sell up to $5,800,000 of its common stock to fund working capital, R&D, and capital expenditures.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- The use of proceeds for 'working capital' and 'R&D' often indicates a need to fund ongoing operational burn rather than specific transformative acquisitions.
📋 Key Facts
- Total offering amount: Up to $5,800,000 in common stock.
- Sales Agent: H.C. Wainwright & Co., LLC.
- Commission rate: 3.0% of the gross sales price.
- Date of agreement: March 20, 2024.
- Purpose of proceeds: Working capital, general corporate purposes, R&D, and capital expenditures.
- Mechanism: At-the-market (ATM) offering via existing S-3 shelf registration.
Cumberland Pharmaceuticals Inc. issued a press release containing company updates and financial results for the three months and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 5, 2024
- Reporting period: Three months and full year ended December 31, 2023
- The filing is a standard disclosure of results of operations and financial condition under Item 2.02.